The historic rise of Viagra has firmly established as a benchmark of pharmaceutical success, however its position within the broader sector now presents questions about future gains. Copycat versions are eroding market share, leading to anxieties that betting on companies heavily reliant to Viagra's former influence could be a dangerous strategy, e